Switch theme
Sign up to access all valuation multiples
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
2020
2.0K+
LTM Revenue $704M
LTM EBITDA $205M
$5.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Wuxi XDC has a last 12-month revenue (LTM) of $704M and a last 12-month EBITDA of $205M.
In the most recent fiscal year, Wuxi XDC achieved revenue of $517M and an EBITDA of $170M.
Wuxi XDC expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Wuxi XDC valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $704M | XXX | $517M | XXX | XXX | XXX |
| Gross Profit | $223M | XXX | $158M | XXX | XXX | XXX |
| Gross Margin | 32% | XXX | 31% | XXX | XXX | XXX |
| EBITDA | $205M | XXX | $170M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 33% | XXX | XXX | XXX |
| EBIT | $181M | XXX | $121M | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $183M | XXX | $137M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Wuxi XDC's stock price is HKD 40 (or $5).
Wuxi XDC has current market cap of HKD 47.9B (or $6.1B), and EV of HKD 44.2B (or $5.6B).
See Wuxi XDC trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.6B | $6.1B | XXX | XXX | XXX | XXX | $0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Wuxi XDC has market cap of $6.1B and EV of $5.6B.
Wuxi XDC's trades at 10.9x EV/Revenue multiple, and 33.1x EV/EBITDA.
Equity research analysts estimate Wuxi XDC's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Wuxi XDC has a P/E ratio of 36.3x.
See valuation multiples for Wuxi XDC and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.1B | XXX | $6.1B | XXX | XXX | XXX |
| EV (current) | $5.6B | XXX | $5.6B | XXX | XXX | XXX |
| EV/Revenue | 8.7x | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBITDA | 29.9x | XXX | 33.1x | XXX | XXX | XXX |
| EV/EBIT | 33.8x | XXX | 46.6x | XXX | XXX | XXX |
| EV/Gross Profit | 27.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 36.3x | XXX | 44.8x | XXX | XXX | XXX |
| EV/FCF | -143.3x | XXX | -56.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWuxi XDC's last 12 month revenue growth is 37%
Wuxi XDC's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $18K for the same period.
Wuxi XDC's rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Wuxi XDC's rule of X is 121% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Wuxi XDC and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 37% | XXX | 41% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 43% | XXX | 109% | XXX | XXX | XXX |
| Rule of 40 | 57% | XXX | 70% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 121% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $18K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wuxi XDC acquired XXX companies to date.
Last acquisition by Wuxi XDC was XXXXXXXX, XXXXX XXXXX XXXXXX . Wuxi XDC acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Wuxi XDC founded? | Wuxi XDC was founded in 2020. |
| Where is Wuxi XDC headquartered? | Wuxi XDC is headquartered in Hong Kong. |
| How many employees does Wuxi XDC have? | As of today, Wuxi XDC has 2.0K+ employees. |
| Who is the CEO of Wuxi XDC? | Wuxi XDC's CEO is Dr. Jincai Li. |
| Is Wuxi XDC publicy listed? | Yes, Wuxi XDC is a public company listed on HKG. |
| What is the stock symbol of Wuxi XDC? | Wuxi XDC trades under 02268 ticker. |
| When did Wuxi XDC go public? | Wuxi XDC went public in 2023. |
| Who are competitors of Wuxi XDC? | Similar companies to Wuxi XDC include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Wuxi XDC? | Wuxi XDC's current market cap is $6.1B |
| What is the current revenue of Wuxi XDC? | Wuxi XDC's last 12 months revenue is $704M. |
| What is the current revenue growth of Wuxi XDC? | Wuxi XDC revenue growth (NTM/LTM) is 37%. |
| What is the current EV/Revenue multiple of Wuxi XDC? | Current revenue multiple of Wuxi XDC is 8.7x. |
| Is Wuxi XDC profitable? | Yes, Wuxi XDC is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Wuxi XDC? | Wuxi XDC's last 12 months EBITDA is $205M. |
| What is Wuxi XDC's EBITDA margin? | Wuxi XDC's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Wuxi XDC? | Current EBITDA multiple of Wuxi XDC is 29.9x. |
| What is the current FCF of Wuxi XDC? | Wuxi XDC's last 12 months FCF is -$42.8M. |
| What is Wuxi XDC's FCF margin? | Wuxi XDC's last 12 months FCF margin is -6%. |
| What is the current EV/FCF multiple of Wuxi XDC? | Current FCF multiple of Wuxi XDC is -143.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
